Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620000600943
Ethics application status
Approved
Date submitted
2/03/2020
Date registered
25/05/2020
Date last updated
25/05/2020
Date data sharing statement initially provided
25/05/2020
Type of registration
Prospectively registered
Titles & IDs
Public title
Seizure Detection Using Kaoskey TRIO Software
Query!
Scientific title
Seizure Detection Using Electrocardiogram Recordings and Kaoskey TRIO Software among participants admitted for inpatient video-EEG monitoring
Query!
Secondary ID [1]
300699
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Epilepsy
316512
0
Query!
Condition category
Condition code
Neurological
314755
314755
0
0
Query!
Epilepsy
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Enrolled in-patients in the Alfred Epilepsy Diagnostic Unit will be asked to wear the eMotion Faros Sensor during the monitoring period, which is a Class IIa medical device that records electrocardiogram (ECG).
It involves the participant wearing 3x5-cent sized sticky electrodes on chest for 24-hours, repeated for each of the 5 days they are in the clinic. with the ECG recorder attached to one of the electrodes.
The device will be administered by the Alfred research assistant assigned to the project.
After the 5 days of this data has been recorded, the Faros sensor/recorder is removed and the 5 days of ECG recordings downloaded.
The TRIO software will then be used to post-process these 5-day recordings and TRIO seizure scoring files generated for later comparison with the independent Alfred Hospital clinical seizure scoring of this same data.
Query!
Intervention code [1]
317022
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
There is currently no device on the market that accurately automatically detects epileptic seizures, especially those that are non-convulsive ('absence seizures').
Video-EEG:
The gold standard throughout the world for seizure diagnosis is manual post-processing of video-EEG monitoring recordings, which will be the comparator in this study.
The video-EEG patient data is collected by setting up continuous recording of 16 channels of EEG from a patient skull cap, and of a continuos video of the patient, for the 5 days the patients are in the clinic.
In this current video-EEG seizure scoring procedure, after the data has been recorded a highly trained clinical specialist scrolls through simultaneous displays of the patient video and 16 channels of EEG to decide when seizures have occurred. This procedure typically takes ~8 hours to score 4-5 days of patient video-EEG data.
The TRIO software analysis of the FAROS 5 days of ECG recording is similarly post-processed at the end of the 5 days.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
323594
0
Seizure events as assessed by high-resolution ECG recordings with the “TRIO” software and with Alfred Video-EEG to be compared to provide false positive / false negative assessment of TRIO performance versus the current clinical standard.
Query!
Assessment method [1]
323594
0
Query!
Timepoint [1]
323594
0
Data will be collected during the five-day inpatient video-EEG monitoring period.
Query!
Secondary outcome [1]
382694
0
The quality of ECG recordings from the compact 2-channel chest-mounted sensor for seizure detection, assessed by sufficient performance of the "TRIO" software.
Query!
Assessment method [1]
382694
0
Query!
Timepoint [1]
382694
0
Data will be collected during the five-day inpatient video-EEG monitoring period.
Query!
Eligibility
Key inclusion criteria
• Is able to provide personally signed and dated informed consent to participate in the study before completing any study related procedures.
• Male or female (aged 18 years or older).
• Possible diagnosis of epilepsy and admitted for inpatient video-EEG monitoring.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• History of a cardiac rhythm or conduction disorder.
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
The TRIO software processes blinded 5-day ECG recordings and provides a list of ’events’ with their start time, end time, duration, and the maximum value of the TRIO index of cardiac disorder (ICD). This TRIO ‘events’ list is then sent to The Alfred Epilepsy Clinic where the TRIO events are compared with their Video-EEG scoring of seizures for the same patient. The false positive and false negative rates for the TRIO scoring are then calculated.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/06/2020
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
31/01/2021
Query!
Actual
Query!
Date of last data collection
Anticipated
28/02/2021
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
16053
0
The Alfred - Melbourne
Query!
Recruitment postcode(s) [1]
29565
0
3004 - Melbourne
Query!
Funding & Sponsors
Funding source category [1]
305142
0
Commercial sector/Industry
Query!
Name [1]
305142
0
Kaoskey Pty Ltd
Query!
Address [1]
305142
0
Unit 6, 3 Central Ave,
Thornleigh, NSW 2120
Query!
Country [1]
305142
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Kaoskey Pty Ltd
Query!
Address
Unit 6, 3 Central Ave,
Thornleigh, NSW 2120
Query!
Country
Australia
Query!
Secondary sponsor category [1]
305501
0
None
Query!
Name [1]
305501
0
Query!
Address [1]
305501
0
Query!
Country [1]
305501
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
305510
0
Alfred Hospital Human Research Ethics Committee
Query!
Ethics committee address [1]
305510
0
The Alfred Hospital 55 Commercial Road Melbourne, VIC3004
Query!
Ethics committee country [1]
305510
0
Australia
Query!
Date submitted for ethics approval [1]
305510
0
04/03/2020
Query!
Approval date [1]
305510
0
24/04/2020
Query!
Ethics approval number [1]
305510
0
HREC/61886/Alfred-2020
Query!
Summary
Brief summary
This is a single-centre, prospective post-market study using a TGA approved Class IIa medical device (“eMotion Faros Sensor”), which records electrocardiogram (ECG) through Kaoskey’s prototyped developed software suite (“TRIO”). Adult (18 years or older) participants admitted for inpatient video-EEG monitoring at The Alfred Hospital meeting eligibility criteria will be invited to participate in the study. Enrolled participants will be asked to wear the eMotion Faros Sensor during the monitoring period. High-resolution ECG recordings will be recorded during the patient’s admission and assessed using the TRIO software suite.
Query!
Trial website
n/a
Query!
Trial related presentations / publications
n/a
Query!
Public notes
Query!
Contacts
Principal investigator
Name
100618
0
Prof Professor Terence J. O’Brien
Query!
Address
100618
0
Department of Neurology Level 4 (Central Block)
The Alfred Hospital 55 Commercial Road Melbourne, VIC 3004
Query!
Country
100618
0
Australia
Query!
Phone
100618
0
+61 0479 041 282
Query!
Fax
100618
0
Query!
Email
100618
0
[email protected]
Query!
Contact person for public queries
Name
100619
0
Professor Terence J. O’Brien/Dr Shobi Sivathamboo
Query!
Address
100619
0
Department of Neurology Level 4 (Central Block)
The Alfred Hospital 55 Commercial Road Melbourne, VIC 3004
Query!
Country
100619
0
Australia
Query!
Phone
100619
0
+61 0479 041 282
Query!
Fax
100619
0
Query!
Email
100619
0
[email protected]
Query!
Contact person for scientific queries
Name
100620
0
Professor Terence J. O’Brien/Dr Shobi Sivathamboo
Query!
Address
100620
0
Department of Neurology Level 4 (Central Block)
The Alfred Hospital 55 Commercial Road Melbourne, VIC 3004
Query!
Country
100620
0
Australia
Query!
Phone
100620
0
+61 0479 041 282
Query!
Fax
100620
0
Query!
Email
100620
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
7199
Informed consent form
379390-(Uploaded-24-04-2020-15-50-09)-Study-related document.docx
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF